A Snapshot of Biomarkers in Psoriasis
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
A persistent long-standing, inflammatory skin condition that is brought on by a variety of factors is psoriasis. It is distinguished by itchy, scaly, reddish plaques, particularly on areas of the body that are frequently chafed, including the extensor sites of the limbs. Recent developments in molecular-targeted therapy that use biologics or small-molecule inhibitors can effectively cure even the worst psoriatic indications. The outstanding clinical outcomes of treatment help to clarify the disease's detrimental consequences on quality of life. Biomarkers that identify deep remission are essential for developing uniform treatment plans. Blood protein markers such as AMPs that are consistently quantifiable can be very helpful in routine clinical practice. The metabolic pathways involve biomarkers that can not only help diagnose psoriasis in a clinical setting but also indicate its severity based on the levels present in the body. Machine learning and AI have made a diagnosis of the expression of genes as biomarkers more accessible. In this article, biomarkers, as well as their key role in psoriasis, are discussed.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Current drug discovery technologies - (2024) vom: 18. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Abhale, Krushna [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Revised 19.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.2174/0115701638278470240312075112 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369899326 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM369899326 | ||
003 | DE-627 | ||
005 | 20240319233611.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240319s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/0115701638278470240312075112 |2 doi | |
028 | 5 | 2 | |a pubmed24n1336.xml |
035 | |a (DE-627)NLM369899326 | ||
035 | |a (NLM)38500289 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Abhale, Krushna |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Snapshot of Biomarkers in Psoriasis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 19.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a A persistent long-standing, inflammatory skin condition that is brought on by a variety of factors is psoriasis. It is distinguished by itchy, scaly, reddish plaques, particularly on areas of the body that are frequently chafed, including the extensor sites of the limbs. Recent developments in molecular-targeted therapy that use biologics or small-molecule inhibitors can effectively cure even the worst psoriatic indications. The outstanding clinical outcomes of treatment help to clarify the disease's detrimental consequences on quality of life. Biomarkers that identify deep remission are essential for developing uniform treatment plans. Blood protein markers such as AMPs that are consistently quantifiable can be very helpful in routine clinical practice. The metabolic pathways involve biomarkers that can not only help diagnose psoriasis in a clinical setting but also indicate its severity based on the levels present in the body. Machine learning and AI have made a diagnosis of the expression of genes as biomarkers more accessible. In this article, biomarkers, as well as their key role in psoriasis, are discussed | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Inflammatory skin disease | |
650 | 4 | |a biomarkers | |
650 | 4 | |a metabolic pathways. | |
650 | 4 | |a psoriasis | |
700 | 1 | |a Veeranjaneyulu, Addepalli |e verfasserin |4 aut | |
700 | 1 | |a Desai, Shivani |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current drug discovery technologies |d 2004 |g (2024) vom: 18. März |w (DE-627)NLM160661455 |x 1875-6220 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:18 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115701638278470240312075112 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 18 |c 03 |